NEW YORK (GenomeWeb News) – Fluidigm today announced a public offering of its shares that is expected to raise $48.7 million in net proceeds.

The South San Francisco, Calif.-based firm is offering 3,660,000 shares of its common stock at $14.25 per share. The offering is expected to close on or about Aug. 21, and proceeds will go toward R&D, commercialization of its products, working capital, and other general corporate use, Fluidigm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Apr
05
Sponsored by
Labcyte

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.